Journal Watch · Journal of Medicinal Chemistry · 2026
Cyclization-Inspired Structural Optimization: Designing Potent Non-nucleoside Reverse Transcriptase Inhibitors with Enhanced Safety and Selectivity.
Collectively, these results highlight <b>16a</b> as a highly promising on-nucleoside reverse transcriptase inhibitor candidate.
TL;DR
Collectively, these results highlight <b>16a</b> as a highly promising on-nucleoside reverse transcriptase inhibitor candidate.
Key findings
- Additionally, <b>16a</b> displayed minimal sensitivity to CYP enzymes, no inhibition of the hERG potassium channel, and no detectable acute toxicity at an in vivo dose of 2 g/kg.
- Collectively, these results highlight <b>16a</b> as a highly promising on-nucleoside reverse transcriptase inhibitor candidate.
What they did
Notably, <b>16a</b> showed negligible cytotoxicity (CC<sub>50</sub> = 196.46 μM) and high selectivity index (SI = 65,789), greatly surpassing ETR (CC<sub>50</sub> > 4.6 μM, SI > 1436) and rilpivirine (RPV) (CC<sub>50</sub> > 4.0 μM, SI > 3989). Moreover, <b>16a</b> and its salt forms exhibited remarkably improved aqueous solubility in acid phosphate-buffered saline, compared to ETR and RPV.
Full abstract (original)
Background: To improve the safety and selectivity of etravirine (ETR), cyclization strategy was employed by replacing the pyrimidine ring with a dihydropteridin-6(5<i>H</i>)-one scaffold affording a series of novel bicyclic tetrahydropteridine derivatives. Among them, compound <b>16a</b> demonstrated exceptional potency against both WT HIV-1 (EC<sub>50</sub> = 3 nM) and seven mutant strains (EC<sub>50</sub> = 14-77 nM), comparable to ETR.
What they did: Notably, <b>16a</b> showed negligible cytotoxicity (CC<sub>50</sub> = 196.46 μM) and high selectivity index (SI = 65,789), greatly surpassing ETR (CC<sub>50</sub> > 4.6 μM, SI > 1436) and rilpivirine (RPV) (CC<sub>50</sub> > 4.0 μM, SI > 3989). Moreover, <b>16a</b> and its salt forms exhibited remarkably improved aqueous solubility in acid phosphate-buffered saline, compared to ETR and RPV.
Results & conclusions: Additionally, <b>16a</b> displayed minimal sensitivity to CYP enzymes, no inhibition of the hERG potassium channel, and no detectable acute toxicity at an in vivo dose of 2 g/kg. Collectively, these results highlight <b>16a</b> as a highly promising on-nucleoside reverse transcriptase inhibitor candidate.
Abstract © the authors / Journal of Medicinal Chemistry (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acs.jmedchem.5c02556 · PubMed 41511861.
Why it matters for pharma & biotech
- Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: small-molecule drug discovery
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Journal of Medicinal Chemistry study find?
Collectively, these results highlight <b>16a</b> as a highly promising on-nucleoside reverse transcriptase inhibitor candidate.
What type of study is this?
It is a research study, published in Journal of Medicinal Chemistry in 2026. Notably, <b>16a</b> showed negligible cytotoxicity (CC<sub>50</sub> = 196.46 μM) and high selectivity index (SI = 65,789), greatly surpassing ETR (CC<sub>50</sub> > 4.6 μM, SI > 1436) and rilpivirine (RPV) (CC<sub>50</sub> > 4.0 μM, SI > 3989).
Where can I read the original paper?
The original is at the publisher via DOI 10.1021/acs.jmedchem.5c02556. PubMed ID: 41511861. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/cyclization-inspired-structural-optimization-designing-potent-non-nucleo-c02556/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides